Search
Flumazenil
go.drugbank.com/drugs/DB01205ApprovedInvestigationalFumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine … receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system.
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingProducts: ANESED-R 1 MG/10 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ADET, ANESED-R 0.5 MG/5 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ADETOcrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalsuch as a doctor's office. … [L42895] It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen.
Products: OCREVUS® CONCENTRADO PARA SOLUCION PARA INFUSION 300MG/10ML, OCREVUS 300 MG/10 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 2 ADETCystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnA covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.
Synonyms: (R,R)-3,3'-dithiobis(2-aminopropanoic acid), β,β'-dithiodialanineOlcegepant
go.drugbank.com/drugs/DB04869InvestigationalBoehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks … Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.
Categories: Calcitonin Gene-Related Peptide Receptor Antagonists, Calcitonin Gene-Related Peptide, analogs & derivativesBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalIt has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. … [A182186] Currently approved for the treatment of depression, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease, brexpiprazole has also been investigated in other psychiatric
Categories: Adrenergic alpha-1 Receptor Antagonists, Serotonin 5-HT1 Receptor AgonistsProducts: REXULTI (BREXPIPRAZOLE) TABLETS 1 MG, REXULTI (BREXPIPRAZOLE) TABLETS 2 MGInositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnNicotinic acid plays an essential role in many important metabolic processes and has been used as lipid-lowering agent. … It is used in food supplements as a source of niacin (vitamin B3), where hydrolysis of 1 g (1.23 mmol) inositol hexanicotinate yields 0.91 g nicotinic acid and 0.22 g inositol.
Categories: Vitamin B Complex, Heterocyclic Compounds, 1-RingFish oil
go.drugbank.com/drugs/DB13961ApprovedInvestigationalNutraceuticalFurthermore, a variety of studies regarding additional potential actions of fish oil omega-3-fatty acids EPA and DHA are ongoing. … Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016.
Synonyms: Omega-3 fish oil, Fish oil containing omega-3 acidsMixtures: BLACKMORES teen multi for GUYS capsule, BLACKMORES teen multi for GIRLS capsulePemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalgrowth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … exhibited gene rearrangements resulting in oncogenic fibroblast growth factor 2 (FGFR2) fusion proteins.
Categories: Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors, Receptor, Fibroblast Growth Factor, Type 2, antagonists & inhibitorsPropantheline
go.drugbank.com/drugs/DB00782ApprovedA muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Categories: Heterocyclic Compounds, 3-RingOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin